Are biomarkers a big market access bonus? us and eu5 payer perspectives and prescribing patterns for key targeted non-small-cell lung cancer agents
May 1, 2015, 00:00
10.1016/j.jval.2015.03.1232
https://www.valueinhealthjournal.com/article/S1098-3015(15)01289-9/fulltext
Title :
Are biomarkers a big market access bonus? us and eu5 payer perspectives and prescribing patterns for key targeted non-small-cell lung cancer agents
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(15)01289-9&doi=10.1016/j.jval.2015.03.1232
First page :
A212
Section Title :
Cancer
Open access? :
No
Section Order :
691